Hexamer Therapeutics, Inc.
PrivateLast Round
Seed Round
Sep 15, 2026
Total Funding Raised
$5.15M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Hexamer Therapeutics, Inc. is a biotechnology company that develops synthetic, peptide-based vaccine platforms for infectious diseases and cancer treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hexamer Therapeutics, Inc. Comparables
Compare Hexamer Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Artificial Cell Technologies, Inc. | 86% | |
| Phoreus Biotechnology, Inc. | 74% | |
| Vaxxinity, Inc. | 66% |
Hexamer Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Sep 15, 2026 | ||||
| Early Funding | Jul 7, 2026 | ||||
| Early Funding | Jan 1, 2024 | ||||
| Grant | Sep 29, 2023 |
Hexamer Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Army Medical Research and Development Command | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 15, 2026
$500K raised in Seed Round.
- Jul 7, 2026
$500K raised in early funding.
Hexamer Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Hexamer Therapeutics, Inc.'s valuation, stock price, and market status.
Is Hexamer Therapeutics, Inc. a public or private company?
Hexamer Therapeutics, Inc. is a private company.
What is the current stock price of Hexamer Therapeutics, Inc.?
Hexamer Therapeutics, Inc. is a private company with no public stock price. Caplight tracks Hexamer Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is Hexamer Therapeutics, Inc. worth (valuation)?
Valuation information for Hexamer Therapeutics, Inc. is not publicly available.
Can I buy Hexamer Therapeutics, Inc. stock?
Hexamer Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Hexamer Therapeutics, Inc.'s last funding round?
Hexamer Therapeutics, Inc.'s most recent funding round was Seed Round on September 15, 2026.
Who are the main investors in Hexamer Therapeutics, Inc.?
Key investors in Hexamer Therapeutics, Inc. include U.S. Army Medical Research and Development Command.
Will Hexamer Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Hexamer Therapeutics, Inc..
How can I track Hexamer Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Hexamer Therapeutics, Inc.'s secondary market activity and sign up for updates.